Technical Analysis for DXCM - DexCom, Inc.

Grade Last Price % Change Price Change
B 124.34 -9.91% -13.67
DXCM closed down 9.91 percent on Friday, April 26, 2024, on 2.72 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
7 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Centerline Cross Bearish 0.00%
Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Earnings Movers Other 0.00%
Multiple of Ten Bearish Other 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 14 hours ago
50 DMA Support about 15 hours ago
2x Volume Pace about 15 hours ago
1.5x Volume Pace about 15 hours ago
3x Volume Pace about 15 hours ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

DexCom, Inc. Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. Its ambulatory product line includes SEVEN PLUS, DexCom G4 system, and DexCom G4 PLATINUM system for adults with diabetes to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia, and to facilitate acute and long-term therapy adjustments. The company's in-hospital product line comprises GlucoClear, a blood-based in-vivo automated glucose monitoring system for use by healthcare providers in the hospital. It also offers SweetSpot, a software platform that enables patients to aggregate and analyze data from diabetes devices and to share it with their healthcare providers. The company markets its products directly to endocrinologists, physicians, and diabetes educators primarily in the United States. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: S&P 500 Medicine Nasdaq 100 Diabetes Telehealth Telemedicine Healthcare Providers Software Platform Glucose Endocrine System Platinum Diabetes Mellitus Medical Monitoring Blood Glucose Monitoring Endocrinology Continuous Glucose Monitor Hyperglycemia Glucose Monitoring Systems Hypoglycemia

Is DXCM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 142.0
52 Week Low 74.75
Average Volume 3,148,325
200-Day Moving Average 115.09
50-Day Moving Average 130.71
20-Day Moving Average 135.88
10-Day Moving Average 133.57
Average True Range 4.98
RSI (14) 36.71
ADX 19.45
+DI 16.80
-DI 29.25
Chandelier Exit (Long, 3 ATRs) 127.06
Chandelier Exit (Short, 3 ATRs) 139.01
Upper Bollinger Bands 143.60
Lower Bollinger Band 128.15
Percent B (%b) -0.25
BandWidth 11.37
MACD Line -0.19
MACD Signal Line 0.93
MACD Histogram -1.117
Fundamentals Value
Market Cap 47.93 Billion
Num Shares 386 Million
EPS 1.30
Price-to-Earnings (P/E) Ratio 95.65
Price-to-Sales 13.52
Price-to-Book 22.45
PEG Ratio 2.46
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 146.43
Resistance 3 (R3) 148.80 143.80 142.75
Resistance 2 (R2) 143.80 138.18 142.62 141.52
Resistance 1 (R1) 134.07 134.70 131.57 131.70 140.29
Pivot Point 129.08 129.08 127.83 127.89 129.08
Support 1 (S1) 119.35 123.45 116.85 116.98 108.39
Support 2 (S2) 114.35 119.97 113.17 107.16
Support 3 (S3) 104.62 114.35 105.93
Support 4 (S4) 102.25